Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphoma, Follicular × Tirzepatide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 6 Endometrial Neoplasms 4 Prostatic Neoplasms 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Breast Neoplasms 2 Weight Loss 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Overweight 1 Opioid-Related Disorders 1 Lymphoma, Follicular 1 Insulin Resistance 1 Hyperplasia 1 Colorectal Neoplasms 1

Interventions

Rituximab 266 Cyclophosphamide 221 fludarabine phosphate 96 Peripheral Blood Stem Cell Transplantation 96 Filgrastim 84 Etoposide 77 Radiotherapy 75 Prednisone 73 Vincristine 72 Lenalidomide 72 Mycophenolic Acid 58 Doxorubicin 58 Bendamustine Hydrochloride 54 Whole-Body Irradiation 53 Cyclosporine 53 fludarabine 48 Melphalan 48 Tacrolimus 43 obinutuzumab 42 Cytarabine 42 Busulfan 41 Methotrexate 39 Antilymphocyte Serum 36 Bortezomib 33 Methylprednisolone 32 Carmustine 31 sargramostim 30 ibrutinib 28 ibritumomab tiuxetan 28 Dexamethasone 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06651177 2026-03-05

TAB

University of Cincinnati

Phase 2 Recruiting

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡